Role of Thymostimulin (TP-1) as an Immunomodulator in Hodgkin’s Disease

  • Stephen Davis
  • Pietro Rambotti
  • Fausto Grignani
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)


With the advent of effective chemotherapy and the introduction of megavoltage radiotherapy techniques, the relapse-free survival (RFS) in previously untreated Hodgkin’s disease has been radically prolonged (Faguet and Davis, 1982). It would appear that the prolonged RFS is, to various degrees, dependent on age, histological subtype, presence of constitutional symptoms, and extent of disease at presentation (Young et al., 1972).


Skin Test Reactivity Serum Lysozyme Lysozyme Level Serum Lysozyme Level Migration Inhibitory Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aisenberg, A. C., 1966, Immunologic status of Hodgkin’s disease, Cancer 19:385–390.CrossRefGoogle Scholar
  2. Bjorkholm, M., Holm, G., Mellstedt, H., and Johnson, B., 1976, Immunodeficiency and prognosis in Hodgkin’s disease, Acta Med. Scand. 295:1273.Google Scholar
  3. Faguet, G. B., and Davis, H. C., 1982, Survival in Hodgkin’s disease: The role of immunocompetence and other major risk factors, Blood 59:938.PubMedGoogle Scholar
  4. Falchetti, R., Bergesi, G., and Caprino, L., 1977, Isolation, partial characterization and biological effects of a calf thymus factor, 3rd European Immunology Meeting, Copenhagen.Google Scholar
  5. Ficher, R., DeVita, V. T., Bostick, F., Vanhaelen, C., Hawsor, D. M., Hubbard, S., and Young, R., 1980, Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin’s disease, Ann. Intern. Med. 92:595–599.Google Scholar
  6. Goodwin, J. S., Messner, R. P., and Peake, G. T., 1977, Prostaglandin producing cells in Hodgkin’s disease, N. Engl. J. Med. 297:963–968.PubMedCrossRefGoogle Scholar
  7. Payne, S.V., Jones, D. B., Haegert, D. G., Smith, J. C., and Wright, D. H., 1976, T and B lymphocytes and Reed-Sternberg cells in Hodgkin’s disease lymph nodes and spleen, Clin. Exp. Immunol. 24:280–286.PubMedGoogle Scholar
  8. Reed, D. M., 1902, On the pathological changes in Hodgkin’s disease with respect to the problem of Homotransplantation, Johns Hopkins Hosp. Rep. 10:133.Google Scholar
  9. Schechtor, G. P., and Soehnlen, F., 1978, Monocyte mediated inhibition of lymphocyte blastogenesis in Hodgkin’s disease, Blood 52:261–271.Google Scholar
  10. Siegel, F. P., 1976, Inhibition of T-cell rosette formation by Hodgkin’s disease serum, N. Engl. J.Med. 295:1313–1316.Google Scholar
  11. Young, R. C., Corder, M. P., Haynes, H. A., DeVito, V. T., 1972a, Delayed hyposensitivity in Hodgkin’s disease, Am. J. Med. 52:63.CrossRefGoogle Scholar
  12. Young, R. C., Corder, M. P., Haynes, H. A., and De Vita, V. T., 1972b, Delayed hypersensitivity in Hodgkin’s disease: A study of 103 patients, Am. J. Med. 52:63–68.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Stephen Davis
    • 1
  • Pietro Rambotti
    • 1
  • Fausto Grignani
    • 1
  1. 1.Istituto di Clinica MedicaUniversita di PerugiaItaly

Personalised recommendations